Preferences of patients for benefits and risks of insomnia medications using data elicited during two phase III clinical trials.

"Disclosure Statements Financial Disclosure. The study was funded by Idorsia Pharmaceuticals Ltd. Sebastian Heidenreich, Melissa Ross, and Gin Nie Chua are employees of Evidera, a business unit of PPD. Sebastian Heidenreich is a minority stockholder of Thermo Fisher Scientific as part of his employment with Evidera. Andrea Phillips-Beyer is an employee of Innovus Consulting Ltd. Innovus Consulting Ltd and Evidera Inc. received funding for the work that is described in this manuscript. Dalma Seboek Kinter is an employee of Idorsia. Non-financial Disclosure. The authors have no non-financial conflict of interest to disclose."

"Disclosure Statements: Financial Disclosure. The study was funded by Idorsia Pharmaceuticals Ltd. Sebastian Heidenreich, Melissa Ross, and Gin Nie Chua are employees of Evidera, a business unit of PPD. Sebastian Heidenreich is a minority stockholder of Thermo Fisher Scientific as part of his employment with Evidera. Andrea Phillips-Beyer is an employee of Innovus Consulting Ltd. Innovus Consulting Ltd and Evidera Inc. received funding for the work that is described in this manuscript. Dalma Seboek Kinter is an employee of Idorsia.: Non-financial Disclosure. The authors have no non-financial conflict of interest to disclose."

"Clinical Trial Information: The data was collected in two phase III clinical trials:: • “Study to Assess the Efficacy and Safety of ACT-541468 in Adult and Elderly Subjects With Insomnia Disorder”; NCT: NCT03545191—https://clinicaltrials.gov/ct2/show/NCT03545191; EudraCT: 2017-004642-20—https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004642-20• “Study to Assess the Efficacy and Safety of ACT-541468 in Adult and Elderly Subjects Suffering From Difficulties to Sleep”; NCT NCT03575104—https://clinicaltrials.gov/ct2/show/NCT03575104; EudraCT: 2017-004643-20—https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004643-20."